Is Novo Nordisk (NYSE:NVO) a full-fledged pharmaceutical company, or does it fall into that "specialty pharmaceutical" niche? Will the company succeed in expanding beyond diabetes and very specialized hormone/protein therapies? Does anybody care so long as the company delivers double-digit revenue growth and returns on capital that approach 40%?

TUTORIAL: Stock Basics

The Strong Get Stronger in Q1
While some analysts seem to be fretting a bit about a "slowdown" in the insulin business for Novo Nordisk, the fact remains that this is one of the fastest-growing major pharmaceutical companies on the planet. Total revenue rose 15% this quarter, with the diabetes franchise growing 16% and the biopharmaceuticals business up 10%. Within diabetes, insulins grew 8% due to continued growth of the analog platform, while Victoza showed nearly 200% growth and delivered over $200 million in revenue on its way to blockbuster status.

Profitability also improved this quarter. Gross margin slid a bit as the company could not completely offset a drag from foreign currency, but the loss was limited to 20 basis points. Operating income grew 24%, though, as sales, administrative and R&D expenses all grew by mid-single-digit amounts. Although the R&D spend looked a bit light this quarter, it looks like more of a timing issue than any sort of philosophical change.

The Diabetes Fortress Still Strong
Novo Nordisk is demonstrating why diabetes is a great franchise for drug companies; the products have to be used over and over again and the reimbursement is strong. Although the company lost some insulin analog share in the United States because of a few managed care contracts that went to Lilly (NYSE:LLY), there is nothing going on in the market that suggests the company is really losing any meaningful ground to Lilly or Sanofi-Aventis (NYSE:SNY) in this market. Likewise, the company is clearly having no problems competing with Merck's (NYSE:MRK) Januvia or Bristol-Myers' (NYSE:BMY) Onglyza.

At the same time, the FDA and would-be competitor missteps are limiting competition. The FDA rejected new insulin formulations from Biodel (Nasdaq:BIOD) and MannKind (Nasdaq:MNKD), and it is unclear if either of these companies will succeed in securing approvals for their oral and inhaled insulin products. Elsewhere, the prospects for Victoza got a big boost from the FDA setback with Bydureon, an anti-diabetes medication that Lilly hopes to co-market as a follow-up to the successful GLP-1 drug Byetta.

An Interesting, but Mixed, Pipeline
As is often the case, Novo had a mix of good and disappointing news on its pipeline. The company is abandoning an oral rapid-acting insulin, while still working on a longer-acting formulation. Data on a would-be rival to Sanofi's Lantus appears to be viable for approval and competitive launch. The company advanced two compounds into Phase 2 studies for rheumatoid arthritis and Crohn's disease (and these are potentially valuable expansions into antibody therapy), but also reported that trials for new applications for Factor 7a and 13 failed.

The Bottom Line
Novo Nordisk clearly stands out from Astra Zeneca (NYSE:AZN), Novartis (NYSE:NVS) and Sanofi-Aventis as a great growth-oriented European pharmaceutical company. It also stands out in terms of its valuation. For investors who doubt just how much investors hate uncertainty and will reward reliable growth (with moderate competitive threats), Novo Nordisk is a great example.

Even allowing for strong ongoing growth in free cash flow and a generous discount rate, Novo Nordisk shares do not look cheap enough today. Though this would be a fantastic stock to buy on a pullback or market correction, it just seems too expensive today. (For related reading, also take a look at Pharmaceutical Sector: Does The FDA Help Or Harm?)

Use the Investopedia Stock Simulator to trade the stocks mentioned in this stock analysis, risk free!

Related Articles
  1. Stock Analysis

    Will WYNN Continue to Rally?

    Wynn Resorts has experienced a rally recently. Will it remain a good bet?
  2. Stock Analysis

    Don't Be Fooled by the Market's Recent Rally

    The bulls won for a bit in early October, but will bears have the last laugh?
  3. Stock Analysis

    Will Twitter's Stock Find its Wings Soon?

    Twitter is an enigma to many investors, but its story is pretty straightforward.
  4. Stock Analysis

    8 Solid Utility Stocks for a Bear Market

    If you're seeking modest appreciation, generous dividend payments and resiliency, consider these eight utility stocks.
  5. Stock Analysis

    Why Phillips 66 (PSX) is a Solid Long-Term Bet

    Here's why Phillips 66 will likely remain one of the world’s largest and most profitable companies for a long time to come.
  6. Stock Analysis

    3 Resilient Oil Stocks for a Down Market

    Stuck on oil? Take a look at these six stocks—three that present risk vs. three that offer some resiliency.
  7. Economics

    Keep an Eye on These Emerging Economies

    Emerging markets have been hammered lately, but these three countries (and their large and young populations) are worth monitoring.
  8. Stock Analysis

    Is Pepsi (PEP) Still a Safe Bet?

    PepsiCo has long been known as one of the most resilient stocks throughout the broader market. Is this still the case today?
  9. Investing

    The ABCs of Bond ETF Distributions

    How do bond exchange traded fund (ETF) distributions work? It’s a question I get a lot. First, let’s explain what we mean by distributions.
  10. Stock Analysis

    The 5 Best Dividend Stocks in the Healthcare Sector

    Learn about the top five dividend stocks of companies operating in the health care sector that generate substantial cash flows to afford high payouts.
  1. How do dividends affect retained earnings?

    When a company issues a cash dividend to its shareholders, the retained earnings listed on the balance sheet are reduced ... Read Full Answer >>
  2. What is the difference between called-up share capital and paid-up share capital?

    The difference between called-up share capital and paid-up share capital is investors have already paid in full for paid-up ... Read Full Answer >>
  3. Why would a corporation issue convertible bonds?

    A convertible bond represents a hybrid security that has bond and equity features; this type of bond allows the conversion ... Read Full Answer >>
  4. How does additional paid in capital affect retained earnings?

    Both additional paid-in capital and retained earnings are entries under the shareholders' equity section of a company's balance ... Read Full Answer >>
  5. What types of capital are not considered share capital?

    The money a business uses to fund operations or growth is called capital, and there are a number of capital sources available. ... Read Full Answer >>
  6. What is the difference between issued share capital and subscribed share capital?

    The difference between subscribed share capital and issued share capital is the former relates to the amount of stock for ... Read Full Answer >>

You May Also Like

Trading Center
You are using adblocking software

Want access to all of Investopedia? Add us to your “whitelist”
so you'll never miss a feature!